A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512399-37-00

Acronym

RA101495-02.302

Enrollment

Registered

2024-07-25

Start date

2020-12-29

Completion date

Unknown

Last updated

2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Myasthenia Gravis

Brief summary

• Incidence of TEAEs

Detailed description

• CFB to Week E12 in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score, • CFB to Week E12 in the Quantitative Myasthenia Gravis (QMG) Score, • CFB to Week E12 in the Myasthenia Gravis Composite (MGC) Score, • CFB to Week E12 in the Myasthenia Gravis – Quality of Life revised (MG-QOL15r) Score

Interventions

DRUGZilbrysq 32.4 mg solution for injection in pre-filled syringe

DRUGZilbrysq 23 mg solution for injection in pre-filled syringe

DRUGZilbrysq 16.6 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• Incidence of TEAEs	—

Secondary

Measure	Time frame
• CFB to Week E12 in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score, • CFB to Week E12 in the Quantitative Myasthenia Gravis (QMG) Score, • CFB to Week E12 in the Myasthenia Gravis Composite (MGC) Score, • CFB to Week E12 in the Myasthenia Gravis – Quality of Life revised (MG-QOL15r) Score	—

Countries

Italy, Norway, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026